Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Mutant Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Early research (Phase 1)Study completedNCT03118817
What this trial is testing

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

Who this might be right for
Solid Tumor
Hanmi Pharmaceutical Company Limited 65
Testing effectiveness (Phase 2)Looking for participantsNCT07581912
What this trial is testing

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Who this might be right for
Colorectal CancerKRAS G12C Mutant Advanced Solid TumorsFulzerasib+1 more
Zhejiang University 40
Early research (Phase 1)UnknownNCT06006793
What this trial is testing

SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD 50
Early research (Phase 1)Active Not RecruitingNCT05533463
What this trial is testing

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 102
Testing effectiveness (Phase 2)Study completedNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Testing effectiveness (Phase 2)Looking for participantsNCT06973564
What this trial is testing

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Who this might be right for
Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd. 294
Testing effectiveness (Phase 2)UnknownNCT06237400
What this trial is testing

ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

Who this might be right for
KRAS G12C Mutant Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 110
Early research (Phase 1)Study completedNCT01986166
What this trial is testing

MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Who this might be right for
Neoplasms
Genentech, Inc. 23
Early research (Phase 1)Looking for participantsNCT07458347
What this trial is testing

Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Who this might be right for
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc. 145
Testing effectiveness (Phase 2)Looking for participantsNCT07417189
What this trial is testing

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Who this might be right for
Solid Tumors, Adult
Abbisko Therapeutics Co, Ltd 401
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435455
What this trial is testing

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 126
Testing effectiveness (Phase 2)Active Not RecruitingNCT06166836
What this trial is testing

Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Who this might be right for
Solid Tumor
InxMed (Shanghai) Co., Ltd. 140
Testing effectiveness (Phase 2)Active Not RecruitingNCT05358249
What this trial is testing

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung+8 more
Novartis Pharmaceuticals 74
Early research (Phase 1)Study completedNCT01787500
What this trial is testing

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Who this might be right for
BRAF NP_004324.2:p.V600XKRAS wt AlleleMetastatic Malignant Solid Neoplasm+4 more
M.D. Anderson Cancer Center 47